title: Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy?
authors.affiliation: New York University School of Medicine, 550 First Avenue, New York, NY, 10016, USA, shelby.davies@nyumc.org.
authors.forename: Shelby
authors.initials: S
authors.lastname: Davies
authors.forename: Gabrielle
authors.initials: G
authors.lastname: Gold-von Simson
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002648:Child; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use; D000069285:Infliximab; D009080:Mucocutaneous Lymph Node Syndrome / Q000188:drug therapy*; D012307:Risk Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab